Calyxt Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Calyxt's estimated annual revenue is currently $7.4M per year.(i)
  • Calyxt's estimated revenue per employee is $155,000

Employee Data

  • Calyxt has 48 Employees.(i)
  • Calyxt grew their employee count by -35% last year.

Calyxt's People

NameTitleEmail/Phone
1
Product Portfolio ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7.8M509%N/AN/A
#2
$7.4M48-35%N/AN/A
#3
$0.9M620%N/AN/A
#4
$0.3M2-91%N/AN/A
#5
$3.6M235%N/AN/A
#6
$0.9M6-33%N/AN/A
#7
$5M323%N/AN/A
#8
$14.7M959%N/AN/A
#9
$14.7M950%$20.5MN/A
#10
$27.9M14413%$39.1MN/A
Add Company

What Is Calyxt?

Founded in 2010, Calyxt, Inc. (previously Cellectis plant sciences, Inc.) is based in New Brighton, Minnesota (USA). The company aims to create healthier crop products such as low trans fat soybean oil, cold storable potato, gluten reduced wheat and low saturated canola oil for the food and agriculture industries. Calyxt is developing a network of partnerships in order to secure accessibility of its food products to consumers.

keywords:N/A

N/A

Total Funding

48

Number of Employees

$7.4M

Revenue (est)

-35%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Calyxt News

2022-04-17 - Calyxt to Host First Quarter 2022 Financial Results ...

Calyxt (Nasdaq: CLXT) is a plant-based synthetic biology company. The Company leverages its proprietary PlantSpring™ technology platform to...

2022-04-17 - Calyxt Inc (CLXT) Stock Falls -20.59% This Week; Should You Buy?

Calyxt Inc (CLXT) stock is down -89.67% over the last 12 months, and the average rating from Wall Street analysts is a Buy.

2022-03-30 - Calyxt Switches Gears Again, But The Cash Clock Keeps Ticking Down

Calyxt is now on to its third business plan, pivoting from gene-edited seed traits to synthetic biology. · The company is looking to produce...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.1M48-4%N/A
#2
$3.5M484%N/A
#3
$3.8M489%N/A
#4
$6.9M487%N/A
#5
$8.2M49-6%N/A